Linnaeus Therapeutics announced the expansion of its ongoing clinical collaboration with Merck to include multiple additional phase 2 cohorts....
Read more
Linnaeus Therapeutics, Inc. announced the presentation of clinical data from its phase 1 dose-escalation study of LNS8801 as a...
Read more
Linnaeus Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for LNS8801 for...
Read more
Linnaeus Therapeutics, Inc. announced that on March 2, 2021 the U.S. Patent and Trademark Office issued U.S. patent 10,934,277...
Read more
Launched at Penn’s UPstart incubator, Haddonfield’s Linnaeus Therapeutics is in the early stages of clinical trials for an anti-cancer...
Read more
Linnaeus Therapeutics announced that it has dosed the first patient in its phase 1/2 adaptive-design clinical trial of its...
Read more
Linnaeus Therapeutics announced that it has entered into a clinical collaboration agreement with Merck to evaluate the combination of...
Read more
Linnaeus Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for LNS8801 for...
Read more
Linnaeus Therapeutics, Inc. announced that its scientific co-founders, Christopher Natale, PhD, Vice President of Research at Linnaeus and Todd...
Read more
Congratulations to Linnaeus for receiving clearance from the FDA for the company's investigational new drug application (IND) for LNS8801...
Read more